Vera Therapeutics, Inc. (VERA)
NASDAQ: VERA · Real-Time Price · USD
34.00
-0.27 (-0.79%)
At close: Sep 18, 2026, 4:00 PM EDT
34.25
+0.25 (0.74%)
After-hours: Sep 18, 2026, 7:48 PM EDT
Vera Therapeutics Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Vera Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $77.36. The average 1-year stock price forecast is 127.53% higher than the current stock price, while the lowest is $34 (0.00%) and the highest is $100 (+194.12%).
Price Target: $77.36 (+127.53%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Vera Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 12 | 12 | 12 | 12 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 14 | 14 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Hold Maintains $34 | Hold | Maintains | $34 | n/a | Sep 16, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Sep 16, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $66 | Buy | Reiterates | $66 | +94.12% | Sep 16, 2026 |
| Wells Fargo | Wells Fargo | Buy Maintains $70 | Buy | Maintains | $70 | +105.88% | Sep 16, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $59 | Buy | Maintains | $59 | +73.53% | Sep 16, 2026 |
Financial Forecast
Revenue This Year
24.79M
Revenue Next Year
221.20M
from 24.79M
Increased by 792.38%
EPS This Year
-6.27
from -4.66
EPS Next Year
-4.37
from -6.27
EPS and Forward PE are based on non-GAAP adjusted numbers.